SAGE Centers is focused on providing outstanding patient care. We also participate in clinical trials designed to find new treatments, and we share information about clinical trials our partners are leading.
Please check this page for clinical trial posts. You may also follow us on Facebook, LinkedIn, Twitter and Instagram to receive updates.
SAGE Direct Test by SAGEMedic Corp
Predicting the Right Treatment for the Right Patient
Chris Apfel, MD, PhD, MBA and Juliana Baratta, MS
Every tumor is different and therefore it has been difficult to predict which therapy is likely to be most effective. The development of next generation sequencing has enabled oncologists to get a better understanding of the underlying genomic mutation and mechanism of an individual cancer. Unfortunately, in the vast majority of cases, a relevant mutation cannot be identified and as of today it is not possible to accurately predict the most effective therapy.
However, the goal of the collaboration between SageMedic Corp. and SAGE Veterinary Centers is to change that. SageMedic Corp. has developed the SAGE Direct Test™ and here is how it works. A patient’s live tumor biopsy will be taken to create in-vitro hundreds of 3D-microtumors that are similar to the patient’s original tumor. Those live, in-vitro microtumors will then be exposed to various treatment options and within less than a week, SageMedic will be able to identify the most effective therapy. We are excited to expand our SAGE Direct Test™ to the veterinarian practice in order to improve the lives of beloved pets and their owners once our development is complete.
Because this is still in the research stage, there is not cost to participate in the study. If you want to learn more about the study, please talk to your oncologist and visit our SageMedic Corp. website.
This trial is available at SAGE Campbell, Dublin, and Redwood City Hospitals.
ImpriMed and SAGE
Improving Future Care for Lymphoma Patients
SAGE invites you and your dog to participate in our long-term research study with ImpriMed, a Palo Alto-based company headed by researchers trained at Stanford University. ImpriMed creates personalized drug combinations to combat cancer and infectious diseases. With pet owners’ consent, SAGE collects canine lymphoma cells with a non-invasive fine-needle aspirate and gives them to ImpriMed to test different chemotherapeutic drugs and concentrations. While there is no immediate health benefit to your pet, voluntarily donating their cells advances veterinary medicine and gives scientists more opportunities to test drugs and drug combinations that could help pets with cancer in the future. There is no cost to participate in this research study. Your SAGE oncologist will extract the cells during your pet’s regular visit. Speak to your SAGE doctor to learn more about how you and your pet can help advance treatment options for dogs with lymphoma.
CANINE LYMPHOMA PATIENTS AND INDUSTRIAL HEMP STUDY BY THE UNIVERSITY OF FLORIDA:
SAGE is enrolling canine lymphoma patients in a study to evaluate the benefits of an Industrial Hemp product while patients are undergoing standard chemotherapy. Patients are randomized to either receive the industrial hemp product or placebo during the study. Clients and doctors are blinded to the randomization. The study will provide some financial assistance for chemotherapy and labwork during the study.